Therapies targeting late events in Alzheimer's disease (AD), including aggregation of
amyloid beta (Aβ) and hyperphosphorylated tau, have largely failed, probably because they …

Reductions of baseline cerebral blood flow (CBF) of∼ 10–20% are a common symptom of
Alzheimer's disease (AD) that appear early in disease progression and correlate with the …

The role of hypoperfusion in Alzheimer's disease (AD) is a vital component to understanding
the pathogenesis of this disease. Disrupted perfusion is not only evident throughout disease …

Objective: To investigate variation in the characteristics of regional cerebral blood flow
(rCBF), brain activity, and intrinsic functional connectivity (FC) across the Alzheimer's …

Alzheimer's disease (AD) is a degenerative disorder characterized by a decreased regional
cerebral blood flow (CBF). It is most likely that a reduction in CBF could displace a pathway …

Cerebral blood flow (CBF) regulation is essential for normal brain function. The mammalian
brain has evolved a unique mechanism for CBF control known as neurovascular coupling …

After nearly a century of inquiry, the cause of Alzheimer's disease (AD) remains to be found.
In this review, basic and clinical evidence is presented that assembles and hypothetically …

There is accumulating evidence suggesting that changes in brain perfusion are present long
before the clinical symptoms of Alzheimer's disease (AD), perhaps even before amyloid-β …

Background Accumulation and deposition of β-amyloid peptides (Aβ) in the brain is a central
event in the pathogenesis of Alzheimer's disease (AD). Besides the parenchymal pathology …

Vascular insults can initiate a cascade of molecular events leading to neurodegeneration,
cognitive impairment, and dementia. Here, we review the cellular and molecular …